Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/149025
Title: A subset of flavaglines inhibits KRAS nanoclustering and activation
Authors: Yurugi, Hajime
Zhuang, Yinyin
Siddiqui, Farid A.
Liang, Hong
Rosigkeit, Sebastian
Zeng, Yongpeng
Abou-Hamdan, Hussein
Bockamp, Ernesto
Zhou, Yong
Abankwa, Daniel
Zhao, Wenting
Désaubry, Laurent
Rajalingam, Krishnaraj
Keywords: Engineering::Bioengineering
Issue Date: 2020
Source: Yurugi, H., Zhuang, Y., Siddiqui, F. A., Liang, H., Rosigkeit, S., Zeng, Y., Abou-Hamdan, H., Bockamp, E., Zhou, Y., Abankwa, D., Zhao, W., Désaubry, L. & Rajalingam, K. (2020). A subset of flavaglines inhibits KRAS nanoclustering and activation. Journal of Cell Science, 133(12). https://dx.doi.org/10.1242/jcs.244111
Project: M4082114
M4082292
Journal: Journal of Cell Science
Abstract: The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loading and oncogene activation in cells at nanomolar concentrations. Treatment with rocaglamide, the first discovered flavagline, inhibited the nanoclustering of KRAS, but not HRAS and NRAS, at specific phospholipid-enriched plasma membrane domains. We further demonstrate that plasma membrane-associated prohibitins directly interact with KRAS, phosphatidylserine and phosphatidic acid, and these interactions are disrupted by rocaglamide but not by the structurally related flavagline FL1. Depletion of prohibitin-1 phenocopied the rocaglamide-mediated effects on KRAS activation and stability. We also demonstrate that flavaglines inhibit the oncogenic growth of KRAS-mutated cells and that treatment with rocaglamide reduces non-small-cell lung carcinoma (NSCLC) tumour nodules in autochthonous KRAS-driven mouse models without severe side effects. Our data suggest that it will be promising to further develop flavagline derivatives as specific KRAS inhibitors for clinical applications.
URI: https://hdl.handle.net/10356/149025
ISSN: 0021-9533
DOI: 10.1242/jcs.244111
Rights: © 2020 The Author(s). All rights reserved. This paper was published by The Company of Biologists Ltd in Journal of Cell Science and is made available with permission of The Author(s).
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SCBE Journal Articles

Files in This Item:
File Description SizeFormat 
jcs244111.pdf6.69 MBAdobe PDFView/Open

SCOPUSTM   
Citations 20

4
Updated on Aug 27, 2021

PublonsTM
Citations 20

2
Updated on Aug 24, 2021

Page view(s)

170
Updated on Jul 3, 2022

Download(s) 50

32
Updated on Jul 3, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.